188 related articles for article (PubMed ID: 35846337)
1. Sulfonylurea and Cancer Risk Among Patients With Type 2 Diabetes: A Population-Based Cohort Study.
Zhao H; Liu Z; Zhuo L; Shen P; Lin H; Sun Y; Zhan S
Front Endocrinol (Lausanne); 2022; 13():874344. PubMed ID: 35846337
[TBL] [Abstract][Full Text] [Related]
2. Time-Varying Risk for Breast Cancer Following Initiation of Glucose-Lowering Therapy in Women with Type 2 Diabetes: Exploring Detection Bias.
Bowker SL; Lin M; Eurich DT; Johnson JA
Can J Diabetes; 2017 Apr; 41(2):204-210. PubMed ID: 27908558
[TBL] [Abstract][Full Text] [Related]
3. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
[TBL] [Abstract][Full Text] [Related]
4. The Risk of TB in Patients With Type 2 Diabetes Initiating Metformin vs Sulfonylurea Treatment.
Pan SW; Yen YF; Kou YR; Chuang PH; Su VY; Feng JY; Chan YJ; Su WJ
Chest; 2018 Jun; 153(6):1347-1357. PubMed ID: 29253553
[TBL] [Abstract][Full Text] [Related]
5. Are sulfonylurea and insulin therapies associated with a larger risk of cancer than metformin therapy? A retrospective database analysis.
Kowall B; Rathmann W; Kostev K
Diabetes Care; 2015 Jan; 38(1):59-65. PubMed ID: 25336750
[TBL] [Abstract][Full Text] [Related]
6. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies.
Thakkar B; Aronis KN; Vamvini MT; Shields K; Mantzoros CS
Metabolism; 2013 Jul; 62(7):922-34. PubMed ID: 23419783
[TBL] [Abstract][Full Text] [Related]
7. DPP4i, thiazolidinediones, or insulin and risks of cancer in patients with type 2 diabetes mellitus on metformin-sulfonylurea dual therapy with inadequate control.
Wong CKH; Man KKC; Chan EWY; Wu T; Tse ETY; Wong ICK; Lam CLK
BMJ Open Diabetes Res Care; 2020 Jun; 8(1):. PubMed ID: 32532851
[TBL] [Abstract][Full Text] [Related]
8. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
Bowker SL; Majumdar SR; Veugelers P; Johnson JA
Diabetes Care; 2006 Feb; 29(2):254-8. PubMed ID: 16443869
[TBL] [Abstract][Full Text] [Related]
9. Metformin vs sulfonylurea use and risk of dementia in US veterans aged ≥65 years with diabetes.
Orkaby AR; Cho K; Cormack J; Gagnon DR; Driver JA
Neurology; 2017 Oct; 89(18):1877-1885. PubMed ID: 28954880
[TBL] [Abstract][Full Text] [Related]
10. Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus.
Qiu H; Rhoads GG; Berlin JA; Marcella SW; Demissie K
Diabetes Obes Metab; 2013 Apr; 15(4):349-57. PubMed ID: 23137378
[TBL] [Abstract][Full Text] [Related]
11. Anti-diabetic therapies and the risk of acute pancreatitis: a nationwide retrospective cohort study from Taiwan.
Chang HY; Hsieh CF; Singh S; Tang W; Chiang YT; Huang WF
Pharmacoepidemiol Drug Saf; 2015 Jun; 24(6):567-75. PubMed ID: 25851403
[TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes.
Xie Y; Bowe B; Gibson AK; McGill JB; Maddukuri G; Al-Aly Z
JAMA Intern Med; 2021 Aug; 181(8):1043-1053. PubMed ID: 34180939
[TBL] [Abstract][Full Text] [Related]
13. Safety of add-on sulfonylurea therapy in patients with type 2 diabetes using metformin: a population-based real-world study.
Hougen I; Whitlock RH; Komenda P; Rigatto C; Clemens KK; Tangri N
BMJ Open Diabetes Res Care; 2021 Dec; 9(2):. PubMed ID: 34969692
[TBL] [Abstract][Full Text] [Related]
14. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study.
Roumie CL; Hung AM; Greevy RA; Grijalva CG; Liu X; Murff HJ; Elasy TA; Griffin MR
Ann Intern Med; 2012 Nov; 157(9):601-10. PubMed ID: 23128859
[TBL] [Abstract][Full Text] [Related]
16. Comparative effect of metformin versus sulfonylureas with dementia and Parkinson's disease risk in US patients over 50 with type 2 diabetes mellitus.
Newby D; Linden AB; Fernandes M; Molero Y; Winchester L; Sproviero W; Ghose U; Li QS; Launer LJ; Duijn CMV; Nevado-Holgado AJ
BMJ Open Diabetes Res Care; 2022 Sep; 10(5):. PubMed ID: 36109050
[TBL] [Abstract][Full Text] [Related]
17. Mortality Associated with Metformin Versus Sulfonylurea Initiation: A Cohort Study of Veterans with Diabetes and Chronic Kidney Disease.
Marcum ZA; Forsberg CW; Moore KP; de Boer IH; Smith NL; Boyko EJ; Floyd JS
J Gen Intern Med; 2018 Feb; 33(2):155-165. PubMed ID: 29181788
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of adverse events of oral antihyperglycemic monotherapy experienced by a geriatric population in a real-world setting: a retrospective cohort analysis.
Asche CV; McAdam-Marx C; Shane-McWhorter L; Sheng X; Plauschinat CA
Drugs Aging; 2008; 25(7):611-22. PubMed ID: 18582148
[TBL] [Abstract][Full Text] [Related]
19. Thiazolidinedione use is associated with reduced risk of dementia in patients with type 2 diabetes mellitus: A retrospective cohort study.
Zhao H; Zhuo L; Sun Y; Shen P; Lin H; Zhan S
J Diabetes; 2023 Feb; 15(2):97-109. PubMed ID: 36660897
[TBL] [Abstract][Full Text] [Related]
20. Association Between Metformin Initiation and Incident Dementia Among African American and White Veterans Health Administration Patients.
Scherrer JF; Morley JE; Salas J; Floyd JS; Farr SA; Dublin S
Ann Fam Med; 2019 Jul; 17(4):352-362. PubMed ID: 31285213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
